Online inquiry

IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9494MR)

This product GTTS-WQ9494MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9494MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11539MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ7805MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ6297MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ5456MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ13641MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ9048MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ4117MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ2703MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW